<DOC>
	<DOCNO>NCT01014936</DOCNO>
	<brief_summary>This open-label , dose-escalation , first-in-man ( FIM ) study design explore MSC2156119J , subject advanced solid tumor respond previous therapy therapy available . Subjects assign one two dose regimen : - Regimen 2 : MSC2156119J three time per week ( e.g. , Days 1 , 3 , 5 ) three week ( 21-day cycle ) - Regimen 3 : MSC2156119J every day three week ( 21-day cycle )</brief_summary>
	<brief_title>First-in-Man , Dose-escalation Trial C-met Kinase Inhibitor MSC2156119J Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Subject read fully understand requirement trial , willing comply trial visit assessment , willing able give inform consent 2 . Histologically cytologically confirm solid tumor , either refractory standard therapy effective standard therapy available 3 . Measurable evaluable disease , define RECIST 1.0 4 . Estimated life expectancy great ( &gt; ) three month 5 . Men woman age great equal ( &gt; = ) 18 year 6 . Women childbearing potential must negative blood pregnancy test Screening Visit . For trial , woman childbearing potential defined woman puberty , unless postmenopausal least 12 month , surgically sterile , sexually inactive . 7 . Subjects partner must willing avoid pregnancy trial three month last trial treatment . Male subject female partner childbearing potential female subject childbearing potential must , therefore , willing use adequate contraception approve investigator , twobarrier method onebarrier method spermicide intrauterine device . This requirement begin two week receive first trial treatment end one month receive last treatment . 8 . ECOG performance status 0 2 9 . Adequate hematological function : Hemoglobin &gt; = 9.0 g/dL Neutrophils &gt; 1.5 x 109/L Platelets &gt; = 75 x 109/L 10 . Adequate liver function : Total bilirubin less equal ( &lt; = ) 1.5 x ULN ( upper limit normal ) AST/ ALT ≤ 2.5 x ULN For subject liver metastasis : Total bilirubin ≤ 1.5 x ULN AST/ ALT ≤ 5 x ULN 11 . Adequate renal function : Serum creatinine &lt; 1.5 x ULN , and/or Calculated creatinine clearance &gt; 60 mL/min 12 . Resolution acute chemotherapy , radiotherapy surgeryrelated AEs Grade &lt; = 2 , except alopecia 13 . Recovery surgical intervention 14 . Subjects enrol MTD determine must present specific c Met alteration ( mutation , overexpression , amplification 1 . Received chemotherapy , immunotherapy , hormonal therapy ( except subject prostate cancer ) , biologic therapy , investigational agent anticancer therapy within 28 day ( five halflives noncytotoxics , whichever short ) , Day 1 trial treatment ( six week nitrosureas mitomycin C ) 2 . Received extensive prior radiotherapy 30 % bone marrow 3 . Symptomatic primary tumor metastasis brain and/or central nervous system , uncontrolled antiepileptic require high dos steroids 4 . Known HIV positivity , active hepatitis C , active hepatitis B 5 . Medical history liver fibrosis/ cirrhosis 6 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) 7 . Medical history difficulty swallowing , malabsorption chronic gastrointestinal disease , condition may hamper compliance and/or absorption test product 8 . Medical history surgery within six week prior enrollment 9 . Impaired cardiac function ( left ventricular ejection fraction &lt; 45 % defined echocardiograph , serious arrhythmia , unstable angina pectoris , congestive heart failure NYHA III IV , myocardial infarction within last 12 month prior trial entry ; sign pericardial effusion ) 10 . Hypertension uncontrolled standard therapy ( stabilize 150/90 mm Hg ) 11 . Peripheral neuropathy Grade &gt; = 2 12 . Medical history significant medical disease , major surgery , psychiatric condition might impair subject 's well preclude full participation trial 13 . Women pregnant nursing 14 . Known drug abuse alcohol abuse 15 . Participation another clinical trial within past 28 day 16 . Requires concurrent treatment nonpermitted drug 17 . Known hypersensitivity trial treatment ingredient 18 . Legal incapacity limit legal capacity 19 . Any reason , opinion principal investigator , precludes subject participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>refractory standard therapy</keyword>
</DOC>